홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Lisdexamfetamine Dimesylate

HCID 11597697
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
608137-33-3
표준 SMILES
CS(=O)(=O)O.CS(=O)(=O)O.C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN
InChIKey
CETWSOHVEGTIBR-FORAGAHYSA-N
분자식
C17H33N3O7S2
평균 분자량
455.6 g/mol
단동위원소 질량
455.17599275

개요

Lisdexamfetamine Dimesylate is the dimesylate form and prodrug of the d-isomer of amphetamine, a non-catecholamine sympathomimetic amine with central nervous system (CNS) stimulating activity. Upon administration, lisdexamphetamine is converted to dextroamphetamine through cleavage of the lysine group. Dextroamphetamine acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from its storage sites in nerve terminals in the CNS, and inhibits their uptake within the mesocorticolimbic system, a major component of the brain reward system, resulting in measurable behavioral changes such as euphoria, mental alertness and excitement and appetite suppression. As a CNS stimulant, this agent may increase blood pressure.

이름 및 식별자

우선 이름
Lisdexamfetamine Dimesylate
IUPAC
(2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide;methanesulfonic acid
영어명
(2S)-2,6-Diamino-N-[(1S)-1-methyl-2-phenylethyl]hexanamide dimethanesulfonate
분자식
C16H29N3O4S
분자량
359.49

이름 및 동의어

Lisdexamfetamine dimesylateVyvanse608137-33-3Lisdexamfetamine mesilateNRP-104SPD489Tyvenselis-dexamfetamine dimesylateNRP104SJT761GEGSNRP 104SPD-489
이름 더 보기
LdxLisdexamfetamine mesylateLisdexamphetamine-DimesylateSpd 489Lisdexamfetamine (mesylate) (CRM)
Lisdexamfetamine dimesilateLisdexamphetamine dimesilateLisdexamfetamine dimethanesulfonateDTXSID60209653Dimesylate, Lis-dexamfetamineelvanseElvanse adultRefChem:57033

데이터베이스 식별자

CAS
608137-33-3
PubChem CID
11597697
DTXSID
DTXSID60209653
ChEMBL
CHEMBL1201178
UNII
SJT761GEGS

물성

구조 계산 물성

극성 표면적
207 Ų
수소 결합 공여자 수
5
수소 결합 수용자 수
9
회전 가능 결합 수
8
무거운 원자 수
29
형식 전하
0
복잡도
344

실험 및 물리화학적 성질

DrugsDEA NFLIS-Drug Category -> Phenethylamines (Amphetamines) (S)
Human Drugs · 3건

Breast Feeding; Lactation; Milk, Human; Adrenergic Agents; Central Nervous System Stimulants; Dopamine Agents; Sympathomimetics; Wakefulness-Promoting Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

물리화학적 성질

인화점
9 ℃ · 9℃
저장 조건
-20 °C · -20°C
물리적 상태
A neat solid

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

독성 정보

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Lisdexamfetamine dimesylate

Ambiguous-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

wgk
1
ridadr
UN1230 - class 3 - PG 2 - Methanol, solution
risk_code
11-23/24/25-39/23/24/25
hazard_code
F,T
safety_code
7-16-36/37-45

화학 및 산업

약리 정보

FDA Pharmacological Classification · 4건

LISDEXAMFETAMINE DIMESYLATE

Central Nervous System Stimulation [PE]; Central Nervous System Stimulant [EPC]

LISDEXAMFETAMINE DIMESYLATE CAPSULES

Central Nervous System Stimulant [EPC]; Central Nervous System Stimulation [PE]

MeSH Pharmacological Classification · 2건

A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here.

Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake.

응용 분야 · 2건

개요ADHD is a neurobehavioral disorder characterized by varying degrees of inattention, hyperactivity, and impulsivity. ADHD is typically diagnosed in childhood and affects 7–12% of the pediatric population in the United States with the condition often enduring into adulthood. While the precise mechanism of action of lisdexamfetamine in treating ADHD is not known, amphetamines are believed to inhibit the reuptake of the neurotransmitters dopamine and noradrenaline (norepinephrine), thereby increasing their presynaptic availability and release into extraneuronal space. The prodrug is constructed by the condensation of D-amphetamine with the activated ester (N-hydroxysuccinimide) of bis-tert-butoxycarbonylprotected L-lysine. Lisdexamfetamine is ultimately generated by treatment with hydrochloric acid in dioxane. The most common adverse events, comparable to other amphetamine formulations, were decreased appetite, insomnia, upper abdominal pain, and irritability. Lisdexamfetamine is contraindicated in patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension, hyperthyroidism, known hypersensitivity to the sympathomimetic amines, glaucoma, a predisposition to agitated states, and a history of drug abuse. In addition, the drug should not be administered during or within 14 days of treatment with monoamine oxidase inhibitors. It has also been noted that psychostimulants may exacerbate symptoms of pre-existing psychotic disorders, so caution and close observation are recommended in this patient population.

관련 반응

15건
반응 기록 만들기
HRID 643241 반응식
HRID 643241생성물로
HRID 1441220 반응식
HRID 1441220생성물로
HRID 1442488 반응식
HRID 1442488생성물로
HRID 1442489 반응식
HRID 1442489생성물로
HRID 1443641 반응식
HRID 1443641생성물로
HRID 2234738 반응식
HRID 2234738생성물로
HRID 2237362 반응식
HRID 2237362생성물로
HRID 2239227 반응식
HRID 2239227생성물로
이전1 / 2 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

용도Treatment of atten tion deficit hyperactivity disorder (ADHD).